Teacher Retirement System of Texas Raises Position in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Teacher Retirement System of Texas grew its holdings in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 38.7% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 662,797 shares of the company’s stock after purchasing an additional 184,915 shares during the period. Teacher Retirement System of Texas owned approximately 0.06% of Teva Pharmaceutical Industries worth $14,608,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. Smithfield Trust Co lifted its holdings in shares of Teva Pharmaceutical Industries by 55.7% during the third quarter. Smithfield Trust Co now owns 2,739 shares of the company’s stock valued at $50,000 after purchasing an additional 980 shares during the last quarter. Wilmington Savings Fund Society FSB bought a new stake in shares of Teva Pharmaceutical Industries during the third quarter valued at approximately $50,000. Ameliora Wealth Management Ltd. bought a new stake in shares of Teva Pharmaceutical Industries during the fourth quarter valued at approximately $66,000. IFP Advisors Inc increased its position in shares of Teva Pharmaceutical Industries by 96.1% during the fourth quarter. IFP Advisors Inc now owns 3,999 shares of the company’s stock valued at $88,000 after acquiring an additional 1,960 shares in the last quarter. Finally, C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors bought a new stake in shares of Teva Pharmaceutical Industries during the fourth quarter valued at approximately $104,000. 54.05% of the stock is currently owned by hedge funds and other institutional investors.

Teva Pharmaceutical Industries Stock Down 0.4 %

Shares of TEVA stock opened at $16.18 on Friday. The stock has a market cap of $18.34 billion, a P/E ratio of -11.16, a PEG ratio of 1.44 and a beta of 0.82. Teva Pharmaceutical Industries Limited has a 52 week low of $12.51 and a 52 week high of $22.80. The company has a quick ratio of 0.75, a current ratio of 0.98 and a debt-to-equity ratio of 2.97. The company’s fifty day simple moving average is $17.79 and its two-hundred day simple moving average is $18.21.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its quarterly earnings results on Wednesday, January 29th. The company reported $0.70 EPS for the quarter, topping the consensus estimate of $0.69 by $0.01. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. Analysts predict that Teva Pharmaceutical Industries Limited will post 2.5 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on TEVA shares. Piper Sandler raised their price target on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an “overweight” rating in a research report on Friday, January 17th. Barclays cut their target price on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating for the company in a research report on Thursday, January 30th. Bank of America cut their target price on shares of Teva Pharmaceutical Industries from $23.00 to $20.00 and set a “buy” rating for the company in a research report on Thursday, March 6th. UBS Group cut their price objective on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating for the company in a research report on Thursday, January 30th. Finally, StockNews.com raised shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a research report on Wednesday. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $23.43.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.